Acquired by CliniSys ApolloLIMS was acquired by CliniSys in 2022, indicating potential alignment with CliniSys customer bases and cross-sell opportunities for integrated LIMS solutions and expanded service offerings.

Public health focus With expertise in public health, diagnostics and toxicology, ApolloLIMS serves a niche that can be leveraged to position enhanced LIMS capabilities for labs in government, disease surveillance, and regulatory reporting sectors.

Mid-market footprint Headquartered in Nashville with a small to mid-sized employee base (11–50), ApolloLIMS presents a focus on personalized solutions and potentially higher LTV through ongoing support and consulting engagements for mid-market labs.

Automation and Ops The value proposition centers on operational excellence through LIMS-driven automation, suggesting upsell opportunities for workflow automation, data integrity, and regulatory compliance modules to labs seeking efficiency gains.

Revenue scale Current revenue range of one to ten million signals a growth-stage profile where targeted expansions, integration partnerships, and customer expansion within existing accounts could yield meaningful revenue uplift.